NO20053748L - Pyrrolopyridazinderivater. - Google Patents

Pyrrolopyridazinderivater.

Info

Publication number
NO20053748L
NO20053748L NO20053748A NO20053748A NO20053748L NO 20053748 L NO20053748 L NO 20053748L NO 20053748 A NO20053748 A NO 20053748A NO 20053748 A NO20053748 A NO 20053748A NO 20053748 L NO20053748 L NO 20053748L
Authority
NO
Norway
Prior art keywords
pyrrolopyridazine derivatives
pyrrolopyridazine
derivatives
pde
tnf
Prior art date
Application number
NO20053748A
Other languages
English (en)
Norwegian (no)
Other versions
NO20053748D0 (no
Inventor
Kazuhiko Ohne
Yuki Sawada
Tsuyoshi Mizutani
Kenichiro Imamura
Yoshito Abe
Makoto Inoue
Kozo Sawada
Mitsuaki Okumura
Original Assignee
Fujisawa Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2003900189A external-priority patent/AU2003900189A0/en
Priority claimed from AU2003903628A external-priority patent/AU2003903628A0/en
Application filed by Fujisawa Pharmaceutical Co filed Critical Fujisawa Pharmaceutical Co
Publication of NO20053748D0 publication Critical patent/NO20053748D0/no
Publication of NO20053748L publication Critical patent/NO20053748L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Neurosurgery (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
NO20053748A 2003-01-09 2005-08-04 Pyrrolopyridazinderivater. NO20053748L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2003900189A AU2003900189A0 (en) 2003-01-09 2003-01-09 Heterocyclic derivatives
AU2003903628A AU2003903628A0 (en) 2003-07-14 2003-07-14 Pyrrolopyridazine derivatives
PCT/JP2003/017091 WO2004063197A1 (en) 2003-01-09 2003-12-26 Pyrrolopyridazine derivatives

Publications (2)

Publication Number Publication Date
NO20053748D0 NO20053748D0 (no) 2005-08-04
NO20053748L true NO20053748L (no) 2005-10-07

Family

ID=32714072

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20053748A NO20053748L (no) 2003-01-09 2005-08-04 Pyrrolopyridazinderivater.

Country Status (22)

Country Link
US (2) US7153854B2 (es)
EP (1) EP1581535B3 (es)
JP (1) JP4671104B2 (es)
KR (1) KR101026819B1 (es)
AR (1) AR042833A1 (es)
AT (1) ATE376549T1 (es)
BR (1) BR0317358A (es)
CA (1) CA2513081C (es)
CY (1) CY1107084T1 (es)
DE (1) DE60317102T3 (es)
DK (1) DK1581535T5 (es)
ES (1) ES2291729T7 (es)
HK (1) HK1088900A1 (es)
IL (1) IL169500A0 (es)
MX (1) MXPA05007462A (es)
NO (1) NO20053748L (es)
NZ (1) NZ541232A (es)
PL (1) PL378245A1 (es)
PT (1) PT1581535E (es)
RU (1) RU2328499C2 (es)
TW (1) TWI332004B (es)
WO (1) WO2004063197A1 (es)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60317102T3 (de) 2003-01-09 2010-02-18 Astellas Pharma Inc. Pyrrolopyridazinderivate
US7030112B2 (en) * 2003-03-25 2006-04-18 Bristol-Myers Squibb Company Pyrrolopyridazine compounds and methods of use thereof for the treatment of proliferative disorders
GB0411056D0 (en) 2004-05-18 2004-06-23 Novartis Ag Organic compounds
WO2006004191A1 (en) * 2004-07-05 2006-01-12 Astellas Pharma Inc. Pyrrolopyridazine derivatives which inhibit pde iv and tnf alfa
KR20070042164A (ko) * 2004-07-05 2007-04-20 아스텔라스세이야쿠 가부시키가이샤 피라졸로피리딘 유도체
GB0422057D0 (en) * 2004-10-05 2004-11-03 Astrazeneca Ab Novel compounds
GB0601951D0 (en) 2006-01-31 2006-03-15 Novartis Ag Organic compounds
AU2007315234A1 (en) 2006-10-30 2008-05-08 Novartis Ag Heterocyclic compounds as antiinflammatory agents
JP2009114123A (ja) * 2007-11-06 2009-05-28 Astellas Pharma Inc ２−アシル−１−アミノピロール化合物の新規製造法
JP2011504505A (ja) 2007-11-21 2011-02-10 デコード ジェネティクス イーエイチエフ 肺および心血管障害を治療するためのビアリールｐｄｅ４抑制剤
ES2442930T3 (es) 2008-01-11 2014-02-14 Novartis Ag Pirimidinas como inhibidores de cinasas
WO2009154230A1 (ja) * 2008-06-17 2009-12-23 持田製薬株式会社 非アルコール性脂肪肝炎の予防／改善・治療薬
EP2346508B1 (en) 2008-09-26 2016-08-24 Intellikine, LLC Heterocyclic kinase inhibitors
WO2010059836A1 (en) * 2008-11-20 2010-05-27 Decode Genetics Ehf Substituted aza-bridged bicyclics for cardiovascular and cns disease
US11033523B2 (en) 2009-04-29 2021-06-15 Amarin Pharmaceuticals Ireland Limited Pharmaceutical compositions comprising EPA and a cardiovascular agent and methods of using the same
KR101849417B1 (ko) * 2010-04-23 2018-04-16 스팀 테크, 엘엘씨 표면 와이퍼 시스템
MX2012013824A (es) * 2010-05-28 2013-03-12 Biocryst Pharm Inc Compuestos heterociclicos como inhibidores de cinasa janus.
MX2013002584A (es) 2010-09-07 2013-04-29 Astellas Pharma Inc Compuesto de pirazoloquinolina.
WO2012034095A1 (en) 2010-09-09 2012-03-15 Irm Llc Compounds and compositions as trk inhibitors
US8637516B2 (en) 2010-09-09 2014-01-28 Irm Llc Compounds and compositions as TRK inhibitors
AR083878A1 (es) 2010-11-15 2013-03-27 Boehringer Ingelheim Int Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento
CA2828219A1 (en) 2011-02-25 2012-08-30 Irm Llc Pyrazolo [1,5-a] pyridines as trk inhibitors
JP5988941B2 (ja) * 2012-09-20 2016-09-07 富士フイルム株式会社 有機銅錯体、有機銅錯体溶液、銅酸化物薄膜、銅酸化物薄膜の製造方法、および、化合物
US10434132B2 (en) * 2013-06-04 2019-10-08 Academia Sinica Galactolipids-enriched plant extracts and the uses thereof
EP3710005B8 (en) * 2017-11-17 2023-06-14 Academia Sinica SUBSTITUTED PYRROLO[2,1,-ALPHA]PHTHALAZINES AND BENZO[g]PYRROL[2,1,-ALPHA]PHTHALAZINES AND THEIR USES IN THE TREATMENT OF CANCER
WO2020079606A1 (en) * 2018-10-17 2020-04-23 Suven Life Sciences Limited Pyrrolo-pyridazine derivatives as muscarinic m1 receptor positive allosteric modulators
CN113825543A (zh) 2019-03-19 2021-12-21 勃林格殷格翰动物保健美国公司 驱虫的氮杂-苯并噻吩和氮杂-苯并呋喃化合物
PE20231205A1 (es) 2020-05-29 2023-08-17 Boehringer Ingelheim Animal Health Usa Inc Compuestos heterociclicos como anthelminticos

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991018903A1 (en) * 1990-05-25 1991-12-12 Fujisawa Pharmaceutical Co., Ltd. Pyrrolopyridazine compounds
AU748787B2 (en) * 1998-05-21 2002-06-13 Shionogi & Co., Ltd. Pyrrolo(1,2-b)pyridazine derivatives having sPLA2 inhibitory effect
IT1303272B1 (it) * 1998-10-29 2000-11-06 Zambon Spa Derivati triciclici inibitori della fosfodiesterasi 4
FR2792938B1 (fr) * 1999-04-28 2001-07-06 Warner Lambert Co NOUVELLES 1-AMINO TRIAZOLO [4,3-a] QUINAZOLINE-5-ONES INHIBITRICES DE PHOSPHODIESTERASES IV
US7105550B2 (en) * 2000-03-01 2006-09-12 Christopher Love 2,4-disubstituted thiazolyl derivatives
AU2001267823A1 (en) * 2000-06-29 2002-01-08 Shionogi And Co., Ltd. Compounds exhibiting x-type spla2 inhibiting effect
JP2004522713A (ja) * 2000-11-17 2004-07-29 ブリストル−マイヤーズ　スクイブ　カンパニー ｐ３８キナーゼ関連疾患の処置方法およびキナーゼインヒビターとして有用なピロロトリアジン化合物
TWI312347B (en) * 2001-02-08 2009-07-21 Eisai R&D Man Co Ltd Bicyclic nitrogen-containing condensed ring compounds
WO2003018020A1 (fr) * 2001-08-23 2003-03-06 Takeda Chemical Industries, Ltd. Inhibiteurs de jnk
US6900208B2 (en) * 2002-03-28 2005-05-31 Bristol Myers Squibb Company Pyrrolopyridazine compounds and methods of use thereof for the treatment of proliferative disorders
DE60317102T3 (de) 2003-01-09 2010-02-18 Astellas Pharma Inc. Pyrrolopyridazinderivate

Also Published As

Publication number Publication date
CA2513081C (en) 2011-04-19
US7317009B2 (en) 2008-01-08
DK1581535T5 (da) 2009-12-21
PL378245A1 (pl) 2006-03-20
RU2005125209A (ru) 2006-01-27
KR101026819B1 (ko) 2011-04-04
JP4671104B2 (ja) 2011-04-13
HK1088900A1 (en) 2006-11-17
ES2291729T7 (es) 2010-03-31
CA2513081A1 (en) 2004-07-29
EP1581535A1 (en) 2005-10-05
BR0317358A (pt) 2005-12-13
AR042833A1 (es) 2005-07-06
ES2291729T3 (es) 2008-03-01
TWI332004B (en) 2010-10-21
TW200418861A (en) 2004-10-01
JP2006515597A (ja) 2006-06-01
DE60317102D1 (de) 2007-12-06
DK1581535T3 (da) 2008-02-11
EP1581535B3 (en) 2009-09-02
EP1581535B9 (en) 2008-03-19
ATE376549T1 (de) 2007-11-15
EP1581535B1 (en) 2007-10-24
US20050075342A1 (en) 2005-04-07
US7153854B2 (en) 2006-12-26
WO2004063197A1 (en) 2004-07-29
NO20053748D0 (no) 2005-08-04
PT1581535E (pt) 2007-12-12
DE60317102T3 (de) 2010-02-18
NZ541232A (en) 2008-02-29
CY1107084T1 (el) 2012-10-24
DE60317102T2 (de) 2009-01-29
MXPA05007462A (es) 2006-01-27
KR20050092738A (ko) 2005-09-22
IL169500A0 (en) 2007-07-04
US20060270678A1 (en) 2006-11-30
RU2328499C2 (ru) 2008-07-10

Similar Documents

Publication Publication Date Title
NO20053748L (no) Pyrrolopyridazinderivater.
NO20054905L (no) 2-acylamino-4-fenyltiazolderivater, fremgangsmate for deres fremstilling og anvendelse av de samme som i terapeutika
NO20081315L (no) Benzokinazolinderivater og deres anvendelse ved behandling av benlidelser
NO20056010L (no) Biaryloksymetylaren-karboksylsyrer
NO20055421L (no) Kinolinderivater som fosfodiestrase-inhibitorer
NO20055887L (no) Pyrido'2, 1-A-isokinoliderivater som DPP-IV-inhibitorer
NO20064201L (no) Glukopyranosylsubstituerte benzolderivater, medikamenter inneholdende slike forbindelser, deres anvendelse og fremstilling
NO20072689L (no) Tetrasykliske indolderivater som antivirale midler
TW200606162A (en) Pyrazolopyridine derivatives
NO20062335L (no) Nye diazaspiroalkaner og deres anvendelse i behandlingen av CCR8 medierte sykdommer
NO20062020L (no) 1-amino-2-oksysubstituerte tetrahydronaftalenderivater, fremgangsmate for fremstilling derav, og deres anvendelse som antiflogistika
JO2353B1 (en) New derivatives of mixed-ring fluoroglycosides and drugs containing these compounds and their use
TNSN05194A1 (en) Substituted n-arylheterocycles, method for production and use thereof as medicaments
NO20050088L (no) Kationisk substituerte difenylazefidinoner, fremgangsmate for deres fremstilling, medikamenter inneholdende nevnte forbindelser og anvendelse derav
CY1116885T1 (el) Υποκατεστημενα παραγωγα κυκλοεξυλομεθυλιου
NO20060147L (no) Benzimidazolderivater, sammensetninger som inneholder slike, fremstilling derav og anvendelse derav
NO20050666L (no) 2,7-substituerte indoler og deres anvendelse som 5-HT6 modulatorer
NO20071137L (no) Nye piperidinderivater for behandling av depresjon
NO20082096L (no) Azaindol-2-karboksamidderivativer
NO20080394L (no) N-(arylalkyl)-1H-pyrrolopyridin-2-karboksamidderivater, fremstilling og anvendelse derav
NO20053809L (no) Diarylmetylindenpiperidinderivater,fremgangsmate for fremstilling derav, og anvendelse derav
NO20052699L (no) 4(fenylpiperazinyl-metyl)benzamid-derivater og deres anvendelse ved behandling av smerte og gastrointestinale lidelser.
NO20083058L (no) Cykloheksylsulfonamidderivater med H3 reseptor aktivitet
DK1926729T3 (da) Benzothiazolcyclobutylaminderivater og deres anvendelse som histamin-3-receptorligander
NO20063865L (no) Heterocyklisk substituerte 7-amino-4-kinolon-3-karboksylsyrederivater, fremgangsmate for fremstilling derav og deres anvendelse som medikamenter